Introduction
Immunization of pregnant women to protect both themselves and their infants is increasingly part of routine care both in the UK and worldwide. Current UK recommendations state that all pregnant women should receive a pertussis-containing vaccine at 16-32 weeks' gestation and the influenza vaccine during the influenza season, at any stage of gestation (1, 2) . There is evidence that these antenatal vaccines are both safe and effective at preventing disease both in the mother and the infant (3) (4) (5) (6) (7) .
Around 60-75% of UK pregnant women received the pertussis vaccine in 2016 (8) , with a marked increase between winter 2015 and 2016 (8) . However, uptake rates for influenza remain suboptimal with recent figures showing that only 43% of eligible pregnant women received the influenza vaccine in 2016 (9) ; thus a significant proportion of pregnant women and their babies remain susceptible to potentially fatal, yet preventable, diseases.
Antenatal immunization also offers the potential to target additional major neonatal pathogens including Group B streptococcus (GBS), the leading cause of sepsis and meningitis in infants under the age of three months (10, 11) . There were around 850 cases (0.95/1000 live births) of culture-proven confirmed GBS cases in the UK and Republic of Ireland in the 13 months from April 2014, resulting in 53 deaths (C. O'Sullivan, pers. comm., unpubl. data), substantially more than the 14 deaths from neonatal pertussis infections in the 2012 pertussis outbreak that prompted the current maternal immunization strategy (12) . Strategies for the prevention of neonatal GBS infection include the risk-based intrapartum antibiotic approach currently used in the UK (13) or a universal swab-based screening program used in the USA, Canada, much of Europe and parts of Australia (14, 15) . Neither strategy impacts on GBS disease beyond the first week of life, and both have the potential to miss cases or contribute to the overuse of antibiotics. An antenatal vaccine against GBS is therefore desirable and clinical trials of candidate GBS vaccines involving over 500 pregnant women have been conducted (16) or are ongoing (17) .
The aim of this study was to investigate the attitudes of pregnant women and the healthcare professionals involved in their care, towards antenatal vaccination, GBS disease and the prospect of a GBS vaccine. Secondary aims included identifying factors affecting vaccine uptake and exploring attitudes towards participating in clinical trials of an antenatal GBS vaccine, and how these could be addressed to optimize uptake in a routine setting and in recruitment for clinical trials. Three different questionnaires were developed for each of the groups of interest (Appendix S1). Inclusion criteria were that the respondent should be over 18, be able to read and write English, and be either pregnant or working as a midwife (including community midwives), obstetric doctor or neonatal doctor at one of the study sites.
Material and methods

Self
The questionnaires were developed after reviewing the literature, using data collected from an online survey of over 1000 women of child-bearing age (18) , and in-depth qualitative work with pregnant women, parents with experience of GBS and maternity professionals (19) . Prior to the national survey, the questionnaires were piloted among the interview and focus group participants and adapted based on their feedback.
Questionnaires were distributed by study staff in antenatal clinic waiting rooms, antenatal classes, multi-professional meetings, staff rooms and via email. Participation was voluntary, the questionnaires were confidential, anonymous and no personal identifying information was collected. Respondents were asked to tick a box at the beginning of the questionnaire to indicate that they understood their answers would be used as part of a research study. Respondents were also given a sealed envelope with the GBS additional information sheet (Appendix S2), which they were instructed to open at a specified point.
Statistical analyses
Questionnaires were returned to a single site (Oxford) and data entered into the OpenClinca database before being exported to the Microsoft EXCEL software program for analysis. Statistical analyses were conducted with Graphpad PRISM software (GraphPad, La Jolla, USA) using Chi-square and Fisher's exact tests. Not all questions were fully completed by every respondent; however, unless otherwise stated, the percentages stated are of all respondants with those who did not complete the question recorded as missing data. For the ranking questions, data were included even if the respondents only ranked some of the options. However, if the respondent only ticked, rather than numbered, boxes, this were recorded as "uninterpretable" and counted as missing data.
Ethical approval
The study was approved by the NRES Committee South Central-Hampshire A ethics committee reference 13/SC/ 0619. The study was funded by a grant from the charity Meningitis Now.
Results
A total of 356 pregnant women, 407 maternity professionals and 118 neonatal doctors were approached to take part in the study, and 300 (84.3%), 306 (75.2%) and 101 (85.6%) completed the questionnaire, respectively. Of these, 31 pregnant women, 33 maternity professionals and four neonatal doctors were excluded from the final analysis as they had not ticked the "permission" box, leaving 269 pregnant women, 273 maternity professionals and 97 neonatal doctors.
The age of the pregnant women ranged from 18 to 46 years, and ethnicity was well matched for the UK population (20). Further demographic details for all groups are shown in Tables 1 and 2 .
In all, 77% (208/269) of the pregnant women recollected being offered at least one vaccination during their current pregnancy (Table 1 ) and 68% (of all respondents, 182/269) indicated that they had received or intended to receive a vaccination during this pregnancy, 19.7% (53/ 269) did not intend to have any vaccinations and 11.2% (30/269) were undecided. Vaccination details for the healthcare professionals are shown in Table 1 . When pregnant women were asked to rank the relative importance of the potential benefits of antenatal vaccination, the highest ranking was protecting their baby from a rare but serious condition, whereas protecting self or others was less important (Figure 1 ). Major concerns about receiving antenatal vaccination were that it might cause harm to the baby and specifically that it may cause a miscarriage ( Figure 2 ). Factors influencing whether the maternity professionals would recommend a vaccine in pregnancy also highlighted the perceived importance of preventing serious conditions, as 24.2% (66) ranked this as the most important consideration. The existence of a national recommendation was also key, with 32.2% (88) of maternity professionals stating this was the factor which would be most influential.
Pregnant women reported receiving information about antenatal immunization from their midwife, obstetrician or general practitioner (187, 69.5%), via leaflets (132, 49.1%) or their own independent research (46, 17%, multiple answers permitted). However, 18% (49) reported they had received no information about antenatal vaccination; these women were significantly less likely to have had, or to intend to have, any antenatal vaccines than those who had received information (Table 2) .
Forty-six percent (124) stated that the most important source of information would be their midwife, with general practitioners and obstetricians being the next most highly ranked sources, and the media being least popular. own research) were more likely to have/to intend to have, a vaccine (Table 2) . Ninety-four percent (258) of maternity professionals agreed that information about vaccination in pregnancy was most appropriately delivered by midwives.
Neither age nor having other children appeared to affect significantly the decision to have an antenatal vaccination, although White British respondents were significantly more likely to have had/to intend to have vaccination than those identifying themselves as Black or White Other, the majority of whom were from elsewhere in Europe (Table 2) .
Both maternity professionals and pregnant women considered 21-30 weeks' gestation to be the most acceptable time in pregnancy for vaccination [pregnant women: 21.2% (57), maternity professionals: 40.7% (111)]. Themes emerging from the free text answers for both groups included a perception that this was a "safer" time, as the baby was more developed and there was less risk of miscarriage. Knowledge about GBS among pregnant women was low with 70% (189) reporting that they didn't know what it was (Figure 3) . Almost all the maternity professionals (269, 98.5%) and neonatal doctors (96, 99%) had some clinical experience of GBS, with similar percentages in both groups reporting they had had discussions with women about GBS (pre-or post-natal) or prescribed/administered antibiotics for GBS. Most (94.8%, 92) of the neonatal doctors had experience of caring for a baby with GBS infection, compared with 61.5% (168) of maternity professionals. Preferred preventive strategies for GBS also varied between the healthcare professional groups; universal screening of all pregnant women was preferred by maternity professionals (116, 42.5%, more than one response permitted) and vaccination by the neonatal doctors (48, 49.5%). Only 32.2% (88) and 24.7% (24) , respectively, felt the current UK risk-based approach was most appropriate.
Before and after reading a leaflet with information about GBS, all respondents were asked how likely they would be to have (pregnant women), recommend (maternity professionals) or support (neonatal doctors) a GBS vaccine. Prior to reading the information, 42.8% (115) of pregnant women stated they would be very/fairly likely to receive the vaccine, which rose to 68.4% (184) after reading the information (Figure 4a ). The shift was less dramatic for maternity professionals (Figure 4b ) and there was virtually no change for neonatal doctors (Figure 4c ).
Respondents were asked whether they would accept, recommend or support a GBS vaccine according to different numbers of previous vaccine recipients in clinical trials ( Figure 5 ). The percentage of pregnant women willing to accept the vaccine increased from 30 to 60% as the hypothetical number of previous recipients increased from 1000 to 10 000. The most frequently cited period of required follow up for adverse outcomes before maternity After reading additional information about the current trial status of GBS vaccines, 23.8% (64) of pregnant women stated that they would be very or fairly likely to take part in a clinical trial of a GBS vaccine. This was not significantly affected by age, parity or ethnicity. The most frequently preferred mode of recruitment was to be invited by their own midwife (49.8%, 134). Internet adverts, for example, on parent forums or emails from the study team were not popular. When the concept of a randomized control trial was explained (i.e. that they may or may not receive the active vaccine and would not be able to choose), the majority of women (177, 65.8%) felt this would not affect their decision to take part; however, 4.5% (12) would be more likely to take part because there was a chance they would not get the vaccine (but still receive the benefits of being in the trial) and 12.6% (34) would be less likely to take part as they would want a guarantee of receiving the vaccine.
Healthcare professionals were generally supportive of GBS vaccine trials with 59.3% (162) of maternity professionals and 74.2% (72) of neonatal doctors very or fairly likely to recommend a pregnant woman to take part in a trial. Almost all (>99%) wanted to be involved in some capacity if their hospital was taking part in a GBS trial, with 78% (213) of maternity professionals willing to discuss the trial, 42% (113) to obtain consent, and 30.5% (82) to administer the vaccine. Neonatal doctors were also keen to be involved with 46.4% (45) willing to be part of the study team and 41.2% (40) to obtain consent.
Among the pregnant women, strong motivators which would make respondents more likely to take part in a clinical trial included having extra scans, being tested themselves for GBS carriage, their baby having regular check-ups for several years and having extra antenatal appointments ( Figure 6 ).
I think it's great that a vaccine is being tried and tested to develop into something which can save lives and limit effects of GBS.
Pregnant woman SP032
For me to take part in the trial, I would need time to think about it, real info on the possible risks and benefits to myself, my baby and others. All discussed with my midwife, so it is face to face.
Pregnant woman OP030
Concerns expressed in the free text section centered on any risk to the baby, particularly of miscarriage.
Risk of miscarriage or other health complications for the baby in utero and beyond. I would be more likely to take part in research concerning my health alone and not that of an unborn child, who has no choice.
Pregnant woman SP003
The potential, unknown, long-term side effects were also a concern and that some women disliked the thought of being a "guinea pig".
In a similar way, maternity professionals and neonatal doctors were concerned about the potential risks to both mother and baby, though the prospect of litigation if things went wrong ranked as the third highest concern and extra workload was also a potential issue.
Discussion
This study provides important new insights on the attitudes of pregnant women and healthcare professionals towards antenatal vaccination and clinical vaccine trials involving pregnant women in the UK. Other attitudinal studies have been conducted mainly in the USA (21) or have focused on single vaccines (22) , and few have assessed the views of healthcare professionals (23) or considered clinical trial participation.
Our findings suggest that provision of information is key to encouraging antenatal vaccine uptake. However, a significant number of women reported they had not been offered information and fears persist about the perceived risk of miscarriage or harm to the baby. Similar concerns have been highlighted in other studies exploring attitudes to maternal immunization, among (8%) women who reported being directly affected by GBS, two indicated having a previous child with GBS infection, 11 a positive GBS swab in this or a previous pregnancy, six knew a friend/family who had a child with GBS infection, one reported that she had had GBS, one that a friend had been told her that recurrent miscarriages could be due to GBS and another did not specify. different populations such as in the USA and Australia (21, 22, 24) . Our data suggest that emphasizing the protection for the baby and the potential severity of the infections, rather than benefit for mother or protection from a common illness, could be more effective at promoting vaccine uptake. This may partly explain the difference in uptake between the pertussis and influenza vaccines, as pertussis is primarily presented as protecting the baby, whereas influenza vaccine programs are primarily designed to protect the pregnant women herself, despite evidence that they can also improve the health of babies (3) . Differences in the perception of the severity of pertussis and influenza for mother and infant have been reported elsewhere, with influenza generally not regarded as serious by any group (25) . However, other factors, such as the different gestation at which these vaccines are recommended, may also play a part.
It is vital that healthcare professionals are aware of the evidence regarding the safety of antenatal vaccination, in particular that there appear to be no increased risks and that there may be additional benefits (3, 6, 7, 26) , such as improved birthweight. Providing a short, written information sheet can be very effective, as demonstrated by the 26% increase in pregnant women likely to accept a GBS vaccine after reading the information sheet, although for the women surveyed here, discussion with a healthcare professional significantly increased the likelihood of acceptance compared with written information alone. As well as having knowledge, maternity professionals need training about how best to communicate key information to all pregnant women. Shortly after the introduction of the antenatal influenza vaccine, Ishola et al. (27) found that only 26% of London midwives felt well prepared to advise women about the influenza vaccine. Evidently this is an important area for development. The specific concern about miscarriage, now of particular relevance to both the influenza and pertussis vaccines, which may be given early in pregnancy, should be actively addressed and reassurance given.
The low level of awareness among pregnant women about GBS is consistent with other UK studies (18) and is perhaps unsurprising in the UK context, where screening for GBS is not routine (13) . However, this could have important implications for the uptake of a future GBS vaccine and our data suggest that implementation will need to be accompanied by an intensive education campaign for both pregnant women and maternity professionals. One other study in the USA, exploring the attitudes of pregnant women towards a hypothetical GBS vaccine, reported a higher potential acceptance rate of 79% (28) , although it is important to note that this was in the context of a routine GBS screening program.
The data regarding pregnant women's potential involvement in a clinical trial are novel and are of practical relevance for those designing and recruiting to studies of antenatal vaccines including not only against GBS but also other major pathogens such as respiratory syncytial virus. Encouragingly, almost a quarter of pregnant women would consider taking part in a hypothetical GBS clinical trial and healthcare professionals were also supportive in that they would be willing to provide significant practical help to the study teams. The involvement of the patient's own clinician is particularly important in Figure 6 . Pregnant women, motivators to take part in a GBS vaccine trial. 1 = most preferred, 9 = least preferred. (n = number of respondents giving that rank to any statement). Of these women, 20% (54) stated that nothing would make them more likely to take part. optimizing participation (29) , although our previous qualitative work has suggested that some maternity professionals may be very ambivalent about clinical vaccine trials (19) . It is reassuring that these were not the views of this more representative sample of UK maternity professionals and suggests that recruiting local staff to be part of the study team could be key to success. Although maternity professionals have the most contact with pregnant women, neonatal doctors could also prove to be a valuable resource as a group which strongly supports antenatal vaccination and could be involved in long-term postnatal follow up, an important motivator for the pregnant women. Contrary to the usual emphasis on minimizing the number of visits to cause as little inconvenience as possible in many standard vaccine studies, it seems that offering additional time, scans and appointments could improve the likelihood of pregnant women participating, whereas incentives such as vouchers or money would have little effect on recruitment. A previous study of mostly non-pregnant women had indicated that those with children might be more likely to take part in a clinical vaccine trial (30) , although the differences here were not significant. In the same study among nonpregnant women, 32% of respondents indicated they would be very/fairly likely to take part (18) compared with 23.8% of the pregnant women surveyed here. However, for women who are pregnant, the scenario of engaging in a vaccine study while pregnant is closer to their current situation and the results shown here are more likely to reflect reality.
There are a number of limitations to this study to be acknowledged. Only respondents who could read and write English were included, thus we excluded important groups who are likely to have particular challenges in accessing information and the vaccines themselves. Future work should make special efforts to reach this underrepresented population. Although the ethnic background of our sample was proportionally representative of the UK population, there were relatively few respondents from ethnic minorities and ethnicity is known to influence attitudes towards healthcare and vaccination (21, 22) . Similarly, caution should be used in extrapolating these data to populations where screening for GBS is routine, in whom background knowledge of GBS among pregnant women may be greater. Though a high proportion of those approached (75-85%) agreed to take part in the study, no data were collected on those who declined to participate, and although a broad range of ages, gestations and parity were included, we cannot rule out responder bias. Only vaccine trials and real life implementation will confirm whether the interventions suggested by these data can increase vaccine uptake.
Antenatal vaccination is an important tool with increasing potential to reduce both maternal and neonatal mortality and morbidity, if it can be delivered effectively. In keeping with previous studies, these data show that both pregnant women and the healthcare professionals have concerns about the use of vaccination in pregnancy but, encouragingly, many are open to the concept of novel vaccines and willing to participate in research to bring these forward. Education of both pregnant women and those caring for them is key to both improve uptake of current and future vaccines and help optimize recruitment for clinical trials to further reduce the burden of neonatal disease both in the UK and worldwide.
